{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:09:38Z","timestamp":1793826578156,"version":"4.6.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002706","name":"AFA F\u00f6rs\u00e4kring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K07CA178258"],"award-info":[{"award-number":["K07CA178258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.eururo.2014.10.010","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T21:42:27Z","timestamp":1414705347000},"page":"619-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification"],"prefix":"10.1016","volume":"67","author":[{"given":"Stacy","family":"Loeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie M.","family":"Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Pickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid V.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.10.010_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schroder","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.10.010_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2009.07.018","article-title":"Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)","volume":"56","author":"Roobol","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MED.0b013e328360332a","article-title":"Prostate cancer overdiagnosis and overtreatment","volume":"20","author":"Klotz","year":"2013","journal-title":"Curr Opin Endocrinal Diabetes Obes"},{"key":"10.1016\/j.eururo.2014.10.010_bib0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.juro.2010.01.001","article-title":"Risk stratification of men choosing surveillance for low risk prostate cancer","volume":"183","author":"Tseng","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOU.0b013e328351dc47","article-title":"Active surveillance in prostate cancer: patient selection and triggers for intervention","volume":"22","author":"Lees","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.eururo.2014.01.027","article-title":"Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review","volume":"65","author":"van den Bergh","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/pcan.2012.38","article-title":"Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center","volume":"16","author":"Abern","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2014.10.010_bib0045","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.juro.2011.12.082","article-title":"Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance","volume":"187","author":"Iremashvili","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0365","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1016\/j.juro.2014.02.1661","article-title":"Reclassification rates are higher among African American men than white men on active surveillance","volume":"191","author":"Sundi","year":"2014","journal-title":"J Urol Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bju.12463","article-title":"The prognostic significance of perineural invasion and race in men considering active surveillance","volume":"114","author":"Cohn","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0060","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.juro.2011.02.220","article-title":"All-cause mortality among military health care beneficiaries with prostate cancer undergoing active surveillance","volume":"185","author":"Cullen","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1569-9056(11)60082-1","article-title":"Effect of baseline characteristics on relative risk of prostate cancer progression in the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial","volume":"10","author":"Fleshner","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0070","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0022-5347(09)61708-0","article-title":"Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer","volume":"181","author":"Smith","year":"2009","journal-title":"J Urol Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0075","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.23502","article-title":"Active surveillance for the management of prostate cancer in a contemporary cohort","volume":"112","author":"Dall\u2019Era","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.10.010_bib0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.juro.2013.09.029","article-title":"Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer","volume":"191","author":"Patel","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0085","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2008.21.2613","article-title":"Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort","volume":"27","author":"Shappley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0090","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-12-3283","article-title":"Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.10.010_bib0095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2014.10.010_bib0105","article-title":"Predicting progression in patients followed with active surveillance for low-risk prostate cancer [abstract 38]","volume":"32","author":"Sternberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0110","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","article-title":"The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer","volume":"185","author":"Whitson","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0115","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.juro.2006.06.103","article-title":"Modeling prostate specific antigen kinetics in patients on active surveillance","volume":"176","author":"Zhang","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0345","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.eururo.2014.02.058","article-title":"ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer","volume":"66","author":"Berg","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0125","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2011.06.027","article-title":"Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program","volume":"61","author":"Bul","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0350","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2013.08.060","article-title":"Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies","volume":"66","author":"Cary","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0135","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.juro.2008.11.109","article-title":"A multi-institutional evaluation of active surveillance for low risk prostate cancer","volume":"181","author":"Eggener","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00432-013-1566-2","article-title":"The impact of baseline [\u22122]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort","volume":"140","author":"Hirama","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0145","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/01.ju.0000141712.79986.77","article-title":"Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer","volume":"172","author":"Klotz","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0150","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1158\/1078-0432.CCR-09-1263","article-title":"Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer","volume":"15","author":"Makarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.10.010_bib0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1464-410X.2007.07190.x","article-title":"Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience","volume":"101","author":"Soloway","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.juro.2007.05.038","article-title":"Predictors of histological disease progression in untreated, localized prostate cancer","volume":"178","author":"Venkitaraman","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22563","article-title":"Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer","volume":"73","author":"Cornu","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2014.10.010_bib0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1464-410X.2009.08791.x","article-title":"DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme","volume":"105","author":"Isharwal","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1464-410X.2009.08887.x","article-title":"Short-term outcomes of the prospective multicentre \u201cProstate Cancer Research International: Active Surveillance\u201d study","volume":"105","author":"van den Bergh","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.juro.2010.09.115","article-title":"Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance","volume":"185","author":"San Francisco","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1569-9056(10)60571-4","article-title":"Is screen-detected prostate cancer in high risk families eligible for active surveillance?","volume":"9","author":"Valeri","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0190","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1055-9965.EPI-12-0411","article-title":"Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance\/monitoring","volume":"21","author":"Burton","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2014.10.010_bib0195","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2012.11648.x","article-title":"Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort","volume":"112","author":"Goh","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0200","first-page":"3","article-title":"Outcome of patients on active surveillance for low-risk prostate cancer in a cohort of British men with low screening penetrance","volume":"106","author":"Mukerji","year":"2010","journal-title":"BJU Int Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0205","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1464-410X.2008.08281.x","article-title":"Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men","volume":"103","author":"van den Bergh","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1464-410X.2007.07175.x","article-title":"Prostate-specific antigen velocity in untreated, localized prostate cancer","volume":"101","author":"Venkitaraman","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/pcan.2008.47","article-title":"Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance","volume":"12","author":"Jhavar","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2014.10.010_bib0220","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.eururo.2008.02.039","article-title":"Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance","volume":"54","author":"van As","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bju.12112","article-title":"Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression","volume":"112","author":"Iremashvili","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0230","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1464-410X.2012.11127.x","article-title":"Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0235","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-410X.2008.08116.x","article-title":"Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time","volume":"103","author":"Ng","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0240","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.juro.2010.09.095","article-title":"Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer","volume":"185","author":"Adamy","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0355","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.juro.2010.02.191","article-title":"The rate of upgrading and upstaging on immediate repeat biopsy in patients eligible for active surveillance is not related to extent of first biopsy","volume":"183","author":"Yee","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1569-9056(11)60995-0","article-title":"Interest of early confirmatory biopsies and centralized pathological review to select prostate cancer patients for active surveillance","volume":"10","author":"Fromont","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2014.10.010_bib0255","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2010.08.027","article-title":"Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment","volume":"58","author":"Soloway","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0260","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bju.12131","article-title":"Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density","volume":"113","author":"Umbehr","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0370","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1111\/bju.12754","article-title":"Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort","volume":"114","author":"Barayan","year":"2014","journal-title":"BJU Int"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2014.10.010_bib0270","article-title":"Factors associated with biopsy progression on active surveillance [abstract 19]","volume":"32","author":"Welty","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0275","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.juro.2012.06.009","article-title":"Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer","volume":"188","author":"Tosoian","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0360","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/j.juro.2014.02.1965","article-title":"Patients that demonstrate Gleason 6 volume progression on active surveillance have a substantially greater risk of grade progression on further follow-up","volume":"191","author":"Komisarenko","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0285","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.juro.2010.06.101","article-title":"Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance","volume":"184","author":"Loblaw","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jjco\/hym161","article-title":"Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer","volume":"38","author":"Kakehi","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0295","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.22161","article-title":"PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section","volume":"120","author":"Khatami","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.10.010_bib0305","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.2012.11295.x","article-title":"Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.10.010_bib0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.juro.2010.03.041","article-title":"Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics","volume":"184","author":"Krakowsky","year":"2010","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2014.10.010_bib0315","first-page":"e831","article-title":"Prostate-specific antigen rises faster in patients with multiple negative biopsies compared to patients followed by active surveillance for low-risk prostate cancer","volume":"183","author":"Pujara","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0320","series-title":"Active surveillance for localized prostate cancer: a new paradigm for clinical management","article-title":"Statistical considerations for patient selection and triggers for intervention in active surveillance","author":"Vickers","year":"2012"},{"key":"10.1016\/j.eururo.2014.10.010_bib0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000145883.01068.5f","article-title":"Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography","volume":"173","author":"Loeb","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","article-title":"Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program","volume":"183","author":"Tosoian","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.10.010_bib0335","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/172460080802300310","article-title":"Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population","volume":"23","author":"Venkitaraman","year":"2008","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.eururo.2014.10.010_bib0340","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814010185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814010185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:03:52Z","timestamp":1759583032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814010185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0302283814010185"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.10.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}